Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer.
Grosgeorges M, Picque Lasorsa L, Pastor B, Prévostel C, Crapez E, Sanchez C, Frayssinoux F, Jarlier M, Pezzella V, Monard L, Ychou M, Thierry AR, Mazard T, Blache P. Grosgeorges M, et al. Among authors: crapez e. Sci Rep. 2023 Feb 15;13(1):2739. doi: 10.1038/s41598-023-29948-4. Sci Rep. 2023. PMID: 36792801 Free PMC article.
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissière F, Laurent-Puig P, Ychou M, Mazard T. Samalin E, et al. Among authors: crapez e. Br J Cancer. 2014 Mar 4;110(5):1148-54. doi: 10.1038/bjc.2013.813. Epub 2014 Jan 9. Br J Cancer. 2014. PMID: 24407191 Free PMC article. Clinical Trial.
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.
Assenat E, Azria D, Mollevi C, Guimbaud R, Tubiana-Mathieu N, Smith D, Delord JP, Samalin E, Portales F, Larbouret C, Robert B, Bibeau F, Bleuse JP, Crapez E, Ychou M, Pèlegrin A. Assenat E, et al. Among authors: crapez e. Oncotarget. 2015 May 20;6(14):12796-808. doi: 10.18632/oncotarget.3473. Oncotarget. 2015. PMID: 25918250 Free PMC article. Clinical Trial.
Circulating DNA as a Strong Multimarker Prognostic Tool for Metastatic Colorectal Cancer Patient Management Care.
El Messaoudi S, Mouliere F, Du Manoir S, Bascoul-Mollevi C, Gillet B, Nouaille M, Fiess C, Crapez E, Bibeau F, Theillet C, Mazard T, Pezet D, Mathonnet M, Ychou M, Thierry AR. El Messaoudi S, et al. Among authors: crapez e. Clin Cancer Res. 2016 Jun 15;22(12):3067-77. doi: 10.1158/1078-0432.CCR-15-0297. Epub 2016 Feb 4. Clin Cancer Res. 2016. PMID: 26847055
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer.
Mirandola A, Kudriavtsev A, Cofre Muñoz CI, Navarro RC, Macagno M, Daoud S, Sanchez C, Pastor B, Pisareva E, Marin MS, Ruiz JG, Piris A, Rodriguez AG, Gonzalez NS, Vivancos A, Quarà V, Mellano A, Borghi F, Corti G, Marchiò C, Sapino A, Bartolini A, Crisafulli G, Bardelli A, Di Maio M, Lossaint G, Frayssinoux F, Crapez E, Ychou M, Soler RS, Fenocchio E, Fernandez Calotti PX, Mazard T, Vivas CS, Elez E, Di Nicolantonio F, Thierry AR. Mirandola A, et al. Among authors: crapez e. EBioMedicine. 2024 Oct;108:105352. doi: 10.1016/j.ebiom.2024.105352. Epub 2024 Sep 19. EBioMedicine. 2024. PMID: 39303668 Free PMC article.
Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers.
Guiu S, Mollevi C, Charon-Barra C, Boissière F, Crapez E, Chartron E, Lamy PJ, Gutowski M, Bourgier C, Romieu G, Simony-Lafontaine J, Jacot W. Guiu S, et al. Among authors: crapez e. Br J Cancer. 2018 Jul;119(1):76-79. doi: 10.1038/s41416-018-0142-6. Epub 2018 Jun 8. Br J Cancer. 2018. PMID: 29880907 Free PMC article.
BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib.
Velazquez C, Orhan E, Tabet I, Fenou L, Orsetti B, Adélaïde J, Guille A, Thézénas S, Crapez E, Colombo PE, Chaffanet M, Birnbaum D, Sardet C, Jacot W, Theillet C. Velazquez C, et al. Among authors: crapez e. Front Oncol. 2023 Mar 17;13:1125021. doi: 10.3389/fonc.2023.1125021. eCollection 2023. Front Oncol. 2023. PMID: 37007122 Free PMC article.
16 results